Skip to main content
. Author manuscript; available in PMC: 2022 May 12.
Published in final edited form as: Pharm Res. 2021 May 12;38(5):803–817. doi: 10.1007/s11095-021-03046-4

Fig. 11. Post-reperfusion administration of NL-1 protects against brain ischemic reperfusion injury.

Fig. 11.

NL-1 was administered to mice 15 min post-reperfusion protected mice from transient brain ischemic-reperfusion injury as seen in brain slices with TTC staining, where red areas are live and white areas are ischemic tissue. Effect of NL-1 treatment (10 mg/kg) on the infarct volume (A) and brain edema (B) of mice treated with NL-1 compared to vehicle treated mice. (C) Vehicle treated tMCAO; (D) NL-1 (10 mg/kg) with tMCAO. Data shown as mean ± S.D. where N = 4-5 mice. Statistical significance *P<0.05.